Biomea Fusion, Inc.: directors' dealings · United States · SEC (Form 4)

About Biomea Fusion, Inc.

Biomea Fusion, Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq market in the United States under the ticker BMEA. The company is focused on metabolic health, with a strategic emphasis on diabetes and obesity. It was founded in August 2017 as a Delaware entity and has since sharpened its corporate identity from a broader biotech profile into a more focused clinical-stage metabolic medicines company. Biomea is headquartered in San Carlos, California, in the San Francisco Bay Area biotech corridor. ([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-enters-2026-focused-executing-key-icovamenib-and?utm_source=openai)) Biomea’s current business is built around two lead oral clinical programs: icovamenib and BMF-650. Icovamenib is described by the company as a potentially first-in-class covalent menin inhibitor being developed for diabetes, including type 2 diabetes patients who are not adequately controlled on standard-of-care therapies, such as GLP-1-based treatments. BMF-650 is a next-generation oral GLP-1 receptor agonist candidate designed for obesity and broader metabolic disease applications. The company’s emphasis on oral therapies is strategically important, because it aims to address a major market need: combining meaningful metabolic efficacy with a more convenient dosing route than the injectable treatments that dominate much of the category today. ([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-enters-2026-focused-executing-key-icovamenib-and?utm_source=openai)) From a competitive standpoint, Biomea remains a clinical-stage, pre-revenue biotech company, which means the investment case is highly dependent on clinical readouts, tolerability, regulatory progress, and funding execution. That said, the company’s positioning is differentiated. Rather than competing only as another diabetes or obesity entrant, Biomea is trying to serve patient subsets that remain underserved by the current standard of care, while simultaneously extending its metabolic platform into obesity through BMF-650. This gives the company exposure to two large and highly competitive therapeutic markets, but with a narrative centered on oral convenience and potential disease-modifying impact if the data continue to validate the mechanism. ([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-enters-2026-focused-executing-key-icovamenib-and/?utm_source=openai)) Recent developments have been centered on clinical execution. In 2026, Biomea announced the first patient dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, for icovamenib in type 2 diabetes. The company also said it is advancing BMF-650, with 28-day weight-loss data expected in the first half of 2026 from a Phase I obesity study. In parallel, Biomea has continued to present data and corporate updates at scientific conferences and has highlighted a capital structure intended to fund key clinical milestones into 2027. For French-speaking investors, BMEA is therefore best viewed as a high-risk, high-upside Nasdaq biotech story in the United States, with value creation hinging on the next set of clinical data and the company’s ability to translate promising biology into registrable assets. ([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-announces-first-patient-dosed-newly-initiated?utm_source=openai))